490 ARSENAL WAY, WATERTOWN, MA
Investor Presentation
Reports Second Quarter 2026 Financial Results and Recent Business Highlights
C4 Therapeutics Elects Andrew J. Hirsch and Others as Class III Directors
Departure of Chief Accounting Officer Mark Mossler at C4 Therapeutics
Reports First Quarter 2026 Financial Results and Recent Business Highlights
Annual Report to Security Holders
By-Laws Amendment - C4 Therapeutics Designates Exclusive Forums
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Free Writing Prospectus